linjc16/ctgov huggingface dataset:
Couples Dynamics and Smoking Cessation

Study Overview
=================
Brief Summary
-----------------
This study is about investigating smoking and attempts to quit smoking in couples. Participation will help determine better treatment efforts for couples who want to quit smoking. All study procedures will be conducted remotely, allowing couples to interact with study personnel through zoom.

Official Title
-----------------
Interpersonal Mechanisms of Smoking Relapse in Romantic Couples

Conditions
-----------------
Smoking, Smoking Cessation, Cessation, Smoking, Smoking Behaviors, Smoking, Cigarette

Intervention / Treatment
-----------------
* Other: No Interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Couples must be in a relationship for more than 6 months with no plans to separate or move in the next 30 days. Participants must smoke at least 5 cigarettes per day for at least the past 2 years. Exclusion Criteria: English non-fluency. Currently pregnant, nursing, or intend to become pregnant within the next 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Both-Quit Group<br>Couples in which both individuals smoke and both individuals would like to quit smoking. | Other: No Interventions<br>* There are no interventions in this study. Participants are observed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cigarette Craving | This measure is obtained through the completion of the Brief Questionnaire of Smoking Urges. | Throughout study completion, an average of 28 days | 
| Confidence in Quit Attempt | This measure is obtained through the completion of the Abstinence Self-Efficacy Questionnaire. | Throughout study completion, an average of 28 days | 
| Mood | This measure is obtained through the completion of the Profile of Mood States Questionnaire. | Throughout study completion, an average of 28 days |
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

Study Overview
=================
Brief Summary
-----------------
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in the fasting state and when blood sugars levels are elevated.

Official Title
-----------------
Effect of Genetic Variation in the GLP-1 Receptor on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetic Humans

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Saline
* Biological: Exendin-9,39


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40 nondiabetic subjects will be recruited. 20 subjects with the AA genotype at rs3765467 and remainder will have the GG genotype. Individuals encompassing the age span of 25-65 years. Exclusion Criteria: Individuals under 25 and over 65 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Saline<br>Saline will be infused during the study | Other: Saline<br>* Saline will serve as the control<br>|
| Active Comparator: Exendin-9,39<br>Exendin-9,39 will be infused during the study | Biological: Exendin-9,39<br>* Exendin-9,39 will block the GLP-1 receptor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin secretion quantified using the minimal model to generate an index of beta-cell responsivity (Φ) |  | This will be calculated from the 0-180 minute data of the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucagon secretion measured by immunoassay |  | This will be averaged over the 0-180 minute data of the study |
Effect of High-flow Nasal Cannula Oxygen on Lung Volumes Determined by Electrical Impedance Tomography

Study Overview
=================
Brief Summary
-----------------
Effect of High-flow nasal cannula oxygen on end-expiratory lung volumes determined by electrical impedance tomography

Detailed Description
-----------------
Prospective clinical study in ICU with patients requiring High-flow nasal cannula oxygen comparing lung volumes determined by electrical impedance tomography and diaphragmatic ultrasound before, during and after High-flow nasal cannula oxygen. Duration of High-flow nasal cannula oxygen is 30 minutes.

Official Title
-----------------
Effect of High-flow Nasal Cannula Oxygen on Lung Volumes Determined by Electrical Impedance Tomography

Conditions
-----------------
Critical Care, High-flow Nasal Cannula Oxygen, Electrical Impedance Tomography, End Expiratory Lung Volume, End Expiratory Lung Impedance, Diaphragmatic Ultrasound

Intervention / Treatment
-----------------
* Other: High-flow nasal cannula oxygen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Adult ICU patients requiring High-flow nasal cannula oxygen Consent of patients or family Arterial line Exclusion Criteria: • Tracheotomized patients Dressings in the thoracic area

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult ICU patients<br> | Other: High-flow nasal cannula oxygen<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| End-expiratory lung volume (EELV) determined by electrical impedance tomography before NIV non invasive ventilation |  | at day 1 | 
| End-expiratory lung volume (EELV) determined by electrical impedance tomography during NIV non invasive ventilation |  | at day 1 | 
| End-expiratory lung volume (EELV) determined by electrical impedance tomography after NIV non invasive ventilation |  | at day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior, medio-anterior, medio-posterior and posterior EELV at each time |  | at day 1 | 
| Diaphragmatic excursion and thickness determined by ultrasound |  | at day 1 | 
| Ventilatory frequency |  | at day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Critical Care, High-flow nasal cannula oxygen, Electrical impedance tomography, End expiratory lung volume, End expiratory lung impedance, Diaphragmatic ultrasound
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

Study Overview
=================
Brief Summary
-----------------
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops

Official Title
-----------------
A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device

Conditions
-----------------
Glaucoma, Open-Angle, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Xalatan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes Exclusion Criteria: History of closed/barely open anterior chamber angle or a history of angle closure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Xalatan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intra-ocular pressure (IOP) level in the study eye. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful eyedrop self-deliveries |  |  | 
| Ease of eyedrop administration |  |  | 
| Change in safety assessments throughout the study period |  |  | 
| Subject preference for the method of drop delivery |  |  |
Faslodex Registry: Fulvestrant in Current Clinical Practice

Study Overview
=================
Brief Summary
-----------------
The sequential administration of endocrine therapies to patients with advanced breast cancer requires the availability of therapies with different modes of actions, so that tumours developing resistance to one agent are not cross resistant to another. Because of its mechanism of action, fulvestrant is distinct from other hormonal therapies, which therefore limits the possibility of cross-resistance with other therapies such as tamoxifen and the aromatase inhibitors (AIs) In this way, patients may benefit from an extended period of endocrine treatment, which has considerable tolerability and quality-of-life advantages over cytotoxic chemotherapy. In Belgium, fulvestrant is indicated for treating postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer with recurrence during or after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen treatment. However, little information is currently available on how fulvestrant is actually being used by physicians in Belgium. The optimum sequence of endocrine treatment for advanced breast cancer has yet to be defined and may depend on certain patient or disease characteristics. Fulvestrant has been granted reimbursement by the Belgian Health authorities (RIZIV/INAMI) with the recommendation to collect the real life data necessary to assess the patients' breast cancer treatment history that may influence the actual endocrine treatment sequence according to physicians current clinical practice..

Official Title
-----------------
Faslodex Registry: a Belgian Observational Study to Evaluate the Use of Fulvestrant in Current Clinical Practice

Conditions
-----------------
Metastatic Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer Exclusion Criteria:
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to collect real life data on the use of fulvestrant in clinical practice in Belgium. Previous therapies (hormonal and chemo) for breast cancer and for advanced breast cancer will be documented for each patient. |  | Visit 1, Visit 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Document treatment during observation period and number of fulvestrant injections |  | Visit 1, Visit 2 | 
| Document reasons for fulvestrant treatment discontinuation |  | Visit 2 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer,, fulvestrant,, postmenopausal,, women, locally advanced,, hormone receptor-positive.
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

Detailed Description
-----------------
XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019.

Official Title
-----------------
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Conditions
-----------------
Pyoderma Gangrenosum

Intervention / Treatment
-----------------
* Biological: Xilonix


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: ≥18 History of pyoderma gangrenosum with or without other systemic disease. Exclusion Criteria: Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer). Treatment with corticosteroids or cyclosporine within the last 2 weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: open label-Xilonix<br>Open label-Xilonix | Biological: Xilonix<br>* IV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Physician's Wound Assessment & Patient's Global Assessment |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pyoderma Gangrenosum
Assessment of Near Vision Capacity in Different Light Intensities

Study Overview
=================
Brief Summary
-----------------
Patients who underwent presbyopic correction with bilateral bifocal intraocular lenses implantation are supposed to have sufficient uncorrected vision capacity for activities of daily living (ADLs) that require near vision acuity (NV), (ie. book reading). However, it is known that light intensity and temperature has a great impact on near vision capacity. Primary objective of this study is to identify the optimal task lighting conditions (in terms of light intensity and temperature) for ADLs that demand near vision acuity for a sample oa patients who underwent presbyopic correction with bilateral bifocal intraocular lenses implantation

Official Title
-----------------
Assessment of Near Vision Capacity in Different Light Intensities and Temperatures in Patients Who Underwent Pseudophakic Presbyopic Correction

Conditions
-----------------
Presbyopia

Intervention / Treatment
-----------------
* Procedure: BB-Phaco


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presbyopia Exclusion Criteria: Glaucoma Corneal pathology Fundus pathology Severe neurological/mental diseases that interfere with visual acuity

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SG<br>Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation | Procedure: BB-Phaco<br>* Phacoemulsification with bilateral bifocal lenses implantation<br>|
| CG<br>Control group (age-matched participants without pseudophakic presbyopic correction) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncorrected Near Vision Acuity (UnVA) | Near Vision Acuity | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Near Vision Capacity (NVC) | NVC score will be measured by the performance score in the following ADLs: a) cellular phone directory entry search, b) reading of message in a cellular phone, c) reading a medical prescription, d) reading a public phonebook | 6 months |
Prospective Use of Real-time MRI

Study Overview
=================
Brief Summary
-----------------
This research study is being done to look at a new MRI imaging software, Siemens Interventional Software, to see if we can improve our ability to see and treat cancerous tumors.

Official Title
-----------------
Prospective Use of Real-time MRI

Conditions
-----------------
Evaluate the Role of Real-time Imaging in Needle Placement, Evaluate the Workflow and Effectiveness of Realtime Imaging Versus Standard MR Imaging

Intervention / Treatment
-----------------
* Procedure: Real-time imaging for MRI-guided procedures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for a percutaneous MR guided procedure Exclusion Criteria: Pregnant Women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Real-time imaging for MRI-guided procedures<br>Real-time imaging for improvement of workflow in MRI-guided procedures | Procedure: Real-time imaging for MRI-guided procedures<br>* Real-time imaging for improvement of workflow in MRI-guided procedures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the time required for each step for needle placement |  | Intra-procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine ease of use of the software |  | Intra-procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, real-time imaging, workflow
Neuronal Correlates of Priming on Goal-directed and Cue-dependent Behavior

Study Overview
=================
Brief Summary
-----------------
The current proposal aims to investigate neuronal correlates of implicit and explicit priming paradigms for changing cue-dependent and goal-directed nutritional behavior.

Detailed Description
-----------------
Food choice and intake is a daily and throughout normal subject. However, for more and more people eating habits and the question of food choice are of increasing interest and in several cases even a problem. The prevalence of obesity has tripled in the last decades and it is even spoken of an obesity epidemic. Life style interventions to lose weight often fail on the long run, also because people fall back into former unhealthy eating habits. Various factors influence our daily food choice, not all of which are apparent to ourselves. Thus, food choice might be goal-directed and therefore conscious and reflective, yet in other circumstances the choice to eat something specific might be based on cue dependent processes which are automatic and thus difficult to control. Since a change in eating-behavior and long-lasting weight loss is most problematic to achieve, the current proposal aims to investigate neuronal correlates of implicit and explicit priming paradigms for changing cue-dependent and goal-directed nutritional behavior.

Official Title
-----------------
Neuronal Correlates of Priming on Goal-directed and Cue-dependent Behavior

Conditions
-----------------
Functional Magnetic Resonance Imaging, Habits, Eating Behavior

Intervention / Treatment
-----------------
* Behavioral: prime


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: experimental: participants with obesity control: participants with normal-weight Exclusion Criteria: currently dieting intolerance to provided food cognitive impairment contraindications for fMRI measurements

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| weight status<br> | |
| mindset<br> | Behavioral: prime<br>* groups be confronted with health or palatability aspects of food items<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in neuronal correlates | Change of BOLD response measured by fMRI | before and 5 minutes after visually presented food items |
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients without atherosclerosis is influenced by prior CMV exposure.

Detailed Description
-----------------
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients without atherosclerosis is influenced by prior CMV exposure.

Official Title
-----------------
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

Conditions
-----------------
Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients who are being evaluated to determine if they have CAD or those who have already been studied and the presence or absence of CAD has been ascertained. No patients who have not been evaluated for CAD.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atherogenesis, Cell Mediated Immunity, Coronary Artery Disease